Humira biosimilars are approved to treat many of the same medical conditions as Humira. But they have varying dosages and concentrations.

The Humira® biosimilars have arrived in the U.S. market. These highly anticipated biosimilars launched against the world's top selling drug of all time1.

Nine adalimumab biosimilars are hitting the market this year, beginning with Amjevita in January. The others — Abrilada, Cyltezo, Hadlima, Hulio, Hyrimoz, ...

HYRIMOZ is a biosimilar to Humira®. This means HYRIMOZ and Humira® are highly similar and have no clinically meaningful differences when it comes to safety, ...

FDA approved Amgen's adalimumab biosimilar in September 2016 [5], and Europe and Colombia's INVIMA approved Amgevita in March 2017 and in April 2020, ...

19 окт. 2023 г. · Adalimumab biosimilars are available as an alternative, cost-effective treatment to Humira®, with similar efficacy and tolerability. Adalimumab ...

In 2023—over 20 years after Humira's launch—9 biosimilars were introduced, creating a disruption in the adalimumab market. The arrival of these biosimilars ...

Biosimilars are FDA-approved versions of original or “reference,” biologics. They are highly similar to reference biologics with no clinically meaningful.

4 апр. 2024 г. · There are currently ten FDA-approved biosimilars to Humira with nine that launched in 2023.* The most recent approval in February 2024 was ...

4 сент. 2024 г. · Its July 2024 Advanced Control Specialty Formulary now contains three preferred Humira options: Hyrimoz, the high-list-price Humira biosimilar ...